Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group

U. Bruntsch; P. Dodion; W.W. ten Bokkel Huinink; H.H. Hansen; H.M. Pinedo; M. Hansen; J. Renard; M. van Glabbeke

Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group

U. Bruntsch, P. Dodion, W.W. ten Bokkel Huinink, H.H. Hansen, H.M. Pinedo, M. Hansen, J. Renard, M. van Glabbeke

VU University medical center

Research output: Contribution to journal › Article › Academic › peer-review

78 Downloads (Pure)

Original language	English
Pages (from-to)	697-699
Journal	European Journal of Cancer and Clinical Oncology
Volume	22
Issue number	6
Publication status	Published - 1986

Access to Document

8035Final published version, 225 KB

Cite this

Bruntsch, U., Dodion, P., ten Bokkel Huinink, W. W., Hansen, H. H., Pinedo, H. M., Hansen, M., Renard, J., & van Glabbeke, M. (1986). Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group. European Journal of Cancer and Clinical Oncology, 22(6), 697-699.

@article{e7c3d8bd1dab4dbfaeb71df727cf051a,

title = "Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group",

author = "U. Bruntsch and P. Dodion and {ten Bokkel Huinink}, W.W. and H.H. Hansen and H.M. Pinedo and M. Hansen and J. Renard and {van Glabbeke}, M.",

year = "1986",

language = "English",

volume = "22",

pages = "697--699",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "6",

}

Bruntsch, U, Dodion, P, ten Bokkel Huinink, WW, Hansen, HH, Pinedo, HM, Hansen, M, Renard, J & van Glabbeke, M 1986, 'Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group', European Journal of Cancer and Clinical Oncology, vol. 22, no. 6, pp. 697-699.

Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group. / Bruntsch, U.; Dodion, P.; ten Bokkel Huinink, W.W. et al.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 6, 1986, p. 697-699.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group

AU - Bruntsch, U.

AU - Dodion, P.

AU - ten Bokkel Huinink, W.W.

AU - Hansen, H.H.

AU - Pinedo, H.M.

AU - Hansen, M.

AU - Renard, J.

AU - van Glabbeke, M.

PY - 1986

Y1 - 1986

M3 - Article

SN - 0277-5379

VL - 22

SP - 697

EP - 699

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 6

ER -